Phage-Derived Antimicrobial Strategies Against Treponema pallidum: Genomic Evidence, Biological Barriers, and Translational Roadmap
Authors:
- Sabit KokanovSKSabit Kokanov
- Aziz NakhanovANAziz Nakhanov
- Nazym SyrymNSNazym Syrym
- Bolat YespembetovBYBolat Yespembetov
- Aibol TerebayATAibol Terebay
- Azamat AbdimukhtarAAAzamat Abdimukhtar
- Yeldos SerikbayYSYeldos Serikbay
- Akbope AbdykalykAAAkbope Abdykalyk
- Aktoty AnarbekovaAAAktoty Anarbekova
- Sabira AlpysbayevaSASabira Alpysbayeva
- Makhpal SarmykovaMSMakhpal Sarmykova
- Alinur ToleukhanATAlinur Toleukhan
Open Access
- 11 November 2026
- journal article
- review article
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1124
Abstract
Syphilis is a systemic sexually transmitted infection caused by Treponema pallidum subsp. pallidum. Despite effective penicillin-based therapy, it remains a major public health challenge due to ongoing transmission, latent infection, congenital disease, and the lack of a licensed vaccine. While the resurgence of bacteriophage research has stimulated interest in alternative antimicrobials for sexually transmitted infections, direct extrapolation of classical lytic phage therapy to T. pallidum is premature. This pathogen is experimentally demanding, grows slowly, lacks validated lytic phages, and possesses an unusual outer membrane with sparse surface-exposed targets. However, comparative genomics has identified prophage-like elements in several Treponema species, while the T. pallidum-lineage genomes examined by Ridgway et al. did not contain detectable prophage regions. This shifts the rationale from endogenous T. pallidum prophage exploitation toward cautious evaluation of heterologous treponemal phage-derived modules, with cross-species target compatibility as a central requirement. This review critically evaluates phage-derived strategies against T. pallidum, discussing biological barriers, prophage genomics, candidate modalities, biosafety filters, and regulatory considerations. We propose a staged translational roadmap progressing from evidence appraisal and candidate prioritization to biochemical validation, direct T. pallidum testing, ex vivo assessment, in vivo validation, and product-class-specific development. Currently, the most credible outputs of this field are research tools, diagnostic binding modules, and early antimicrobial prototypes rather than clinical phage therapy for syphilis.Keywords
Funding Information
- Committee of Science of the Ministry of Science and Higher Education of the Republic of Kazakhstan (AP23489672)
This publication has 75 references indexed in Scilit:
- Refocusing syphilis vaccine research on preventing vertical transmissionThe Lancet Microbe, 2025
- Understanding phage Receptor-binding protein interaction with host surface receptor: the key for phage-Mediated detection and elimination of Pseudomonas aeruginosaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2025
- A novel phage receptor-binding protein as a rapid and specific biorecognition tool for detecting Campylobacter jejuniInternational Journal of Food Microbiology, 2025
- Implementation challenges of personalised phage therapyThe Lancet, 2025
- Strategies for developing phages into novel antimicrobial tailocinsTrends in Microbiology, 2024
- Bacteriophage-based advanced bacterial detection: Concept, mechanisms, and applicationsBiosensors and Bioelectronics, 2021
- In Vitro Cultivation of the Syphilis Spirochete Treponema pallidumCurrent Protocols, 2021
- Marine DNA Viral Macro- and Microdiversity from Pole to PoleCell, 2019
- Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant BacteriaCell Host & Microbe, 2019
- The Treponema pallidum Outer Membrane2017